The idea was already in the pipeline but this time, the gestation is over for these French researchers who have just filed this week the patent for a candidate vaccine against Covid-19, administered by the nasal route, blocking the infection. at his stage initial.
You will also be interested
According to the National Research Institute foragriculture, food and the environment (INRAE), the pre-clinical tests of this vaccine made of protein viral, encapsulated in nanoparticles based onstarch and lipids, showed “very positive” results in mice and golden hamsters. These results have not yet been published in a scientific journal, however.
According to INRAE and the University of Tours, the added value of this vaccine lies in its ability to cut transmission between individuals, by acting directly on the mucous nasal. ” Unlike intramuscular vaccines, only vaccines administered by the nasal route would be able to prevent the presence of virus in the body. nose, initial stage of infection. They indeed induce immunity at the level of nasal mucous membranes, door entry point and place of multiplication of the virus “, Explain the researchers in a press release.
Promising results on animals
« Experiments have shown that the vaccine stops the disease very early. transmission. I work on animals that are infected: two days later, I notice that the viral load in the lungs is explosive. If I look at the same on animals that have been vaccinated and infected, I cannot find any trace of the virus in the lungs. », Specifies the head of the BioMAP research team Isabelle Dimier-Poisson.
This vaccine without adjuvant, which relies on researchers and industrialists based in France, could also serve as a reminder in the population already vaccinated ” to prevent disease transmission “. According to the researcher, BioMAP succeeded in obtaining “ 100% survival “On mice vaccinated, then infected with Covid-19, against” 100% mortality On unvaccinated mice.
The research team hopes to start as soon asfall the production phase with a view to a clinical phase in the second half of 2022. The marketing is scheduled for 2023. ” Technically, the vaccine will be administered using a small adapter placed at the end of a needleless syringe, allowing diffusion within the nasal cavity », Specified INRAE.
The work of the BioMap team at Inrae and the University of Tours is based on a nanoparticle vaccine developed against toxoplasmosis, with ” 100% efficiency on primates».
Interview with Isabelle Dimier-Poisson, University professor, head of the BioMAP Inrae-University of Tours research team in charge of the vaccine project. @ Inrae, YouTube
Interested in what you just read?
.
